Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years

Conclusion: [177Lu]-PSMA-I&T RLT in mCRPC patients at least 80 y old is safe and effective, comparable to previously published data on non–age-selected cohorts with a low rate of high-grade toxicities. Chemotherapy-naïve patients showed a better and longer response to therapy than taxane-pretreated patients. [177Lu]-PSMA RLT seems to be a meaningful treatment option for older patients.

Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Tauber, R., Knorr, K., Retz, M., Rauscher, I., Grigorascu, S., Hansen, K., DAlessandria, C., Wester, H.-J., Gschwend, J., Weber, W., Eiber, M., Langbein, T. Tags: Clinical Investigations Source Type: research